![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 20, Issue 2, 658-672, January 15, 2009
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
*Department of Molecular Microbiology and Immunology, Johns Hopkins University School of Public Health, Baltimore, MD 21205; and Department of Cell Biology, Yale University School of Medicine, New Haven, CT 06520
Submitted May 14, 2008;
Revised November 3, 2008;
Accepted November 4, 2008
Monitoring Editor: Howard Riezman
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
). Toxoplasma gondii, a leading opportunistic parasite in immunosuppressive conditions, contains significant amounts of cholesterol though it lacks the genes for sterol synthesis and modification (Coppens et al., 2000). Parasite cholesterol originates from low-density lipoproteins (LDL) that have been internalized into host cell endocytic compartments. The availability of host cholesterol has a direct impact on Toxoplasma development inside its parasitophorous vacuole (PV) because LDL deprivation induces parasite encystation, whereas overabundance of these lipoproteins stimulates parasite replication (Nishikawa et al., 2005). The dependence on exogenous sources of cholesterol for the proper development of the parasite implies that Toxoplasma must have developed mechanisms for acquiring, transporting, and sorting this lipid. We demonstrated that T. gondii uses protective mechanisms such as reverse cholesterol transport (Sehgal et al., 2005) and cholesterol storage to balance the influx of cholesterol (Nishikawa et al., 2005). The existence of machineries that shuttle cholesterol between the parasite plasma membrane and organelles is implied by the observation that cholesterol is compartimentalized within T. gondii (Coppens and Joiner, 2003). However, nothing is known about the mechanisms implicated in translocating cholesterol across Toxoplasma membranes and maintaining the nonuniform distribution of this lipid among organelles. The unique nature of organelles present in T. gondii and the original features in the parasite physiology augur the existence of unusual cholesterol homeostatic pathways.
Cholesterol can desorb from membranes without the assistance of proteins, but this movement is relatively slow compared with rate at which sterols are trafficked between membranes. In general, cholesterol is moved among cellular compartments by a combination of vesicular and nonvesicular pathways (Prinz, 2007). Several proteins have been proposed to contribute to intracellular sterol trafficking and distribution. These include cytosolic sterol transfer proteins that move sterol between membranes and integral membranes proteins that mediate sterol efflux, and perhaps intracellular sterol transfer. Sterol carrier protein-2 (SCP-2), also known as nonspecific lipid transfer protein, is a 13.3-kDa protein conserved among bacteria, archea, and eukaryotes (Gallegos et al., 2001). 3-D structural analysis of this protein from different species reveals the conservation of a unique fold that forms a hydrophobic tunnel suitable for the binding of various lipids (Dyer et al., 2003). Indeed, in vitro studies report the ability of SCP-2 to transfer not only sterols but also phospholipids, fatty acids, and fatty acyl-CoA between membranes. SCP-2 is specifically targeted to peroxisomes via a C-terminal peroxisomal targeting signal 1 (PTS1), where it is likely involved in peroxisomal β-oxidation of fatty acids. Interestingly, SCP-2–deficient mice show accumulation of methyl-branched fatty acids, which suggests also a physiological role for SCP-2 in 
-fatty acid oxidation (Mukherji et al., 2002).
SCP-2 is part of a large family of proteins that comprises several enzymes involved in lipid metabolism. The function of SCP-2 at the C terminus of multidomain proteins is still enigmatic. To gain a wider perspective into the biological significance of conserved SCP-2, we have characterized a unique ancestral variant of the D-bifunctional protein (DBP) expressed in T. gondii. Although DBP homologues present in fungi and animals contain the three domains D-3-hydroxyacyl-CoA dehydrogenase, enoyl-CoA hydratase, and SCP-2, Toxoplasma DBP consists of one N-terminal D-3-hydroxyacyl-CoA dehydrogenase domain connected to two C-terminal SCP-2 domains (Edqvist and Blomqvist, 2006). The reliance of T. gondii on host cholesterol for growth implies that the parasite must be proficient at moving this lipid from its surface to intracellular compartments. Toxoplasma is incompetent to internalize exogenous molecules by endocytosis that precludes a role for plasma membrane-derived vesicles in cholesterol internalization. As an alternative mechanism, SCP-2 may contribute to the uptake and intracellular circulation of cholesterol in the parasite.
Our results demonstrate that T. gondii DBP undergoes multiple cleavage steps, sequentially releasing the SCP-2 domains from the enzymatic portion. Both Toxoplasma SCP-2 domains display selective affinity for lipids, show cytosolic and/or vesicular localization, and enhance lipid uptake and metabolism, suggesting their role in lipid shuttling within the parasite. This work represents the first evidence for the existence of a functional SCP-2 domain in a protozoan parasite.
|
MATERIALS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Mammalian Cell Lines, Culture Conditions, and Parasite Propagation
Mammalian cell lines used included: primary human foreskin fibroblasts (HFFs), COS-7 cells, normal human fibroblasts (NHFs), the human Zellweger syndrome fibroblasts (ZFs) obtained from the Human Genetic Mutant Cell Repository (GM04340; Camden, NJ) and NIH3T3 mouse fibroblasts stably expressing enhanced EGFP-human catalase (generous gift from Dr. A. Kaasch, Johns Hopkins University) in the presence of 500 µg/ml zeocin. All these cells were grown as monolayers and cultivated in -minimum essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, and penicillin/streptomycin (100 U/ml/100 µg/ml) as described previously (Coppens et al., 2000). The tachyzoite RH strain of Toxoplasma gondii was propagated in vitro by serial passage in HFFs (Roos et al., 1994).
Sequence Analysis
Nucleotide and amino acid sequences were searched against the T. gondii database (www.toxodb.org) and the National Center for Biotechnology Information database using the BLAST algorithm (Altschul et al., 1997). Multiple sequence alignment was created using ClustalW, and the resulting similarities were then visualized by subjecting the alignment to Boxshade (www.ch.embnet.org). Percentage of identity and similarity were calculated using standard tools for sequence analysis from National Center for Biotechnology Information (ncbi.nlm.nih.gov).
Cloning of Full-Length cDNA Encoding TgHAD-2SCP-2
Several sequences for the SCP-2 domain were identified in the genome and expressed sequence tags (ESTs) of the Toxoplasma database. The open reading frame (ORF) of TgHAD-2SCP-2 was amplified from a T. gondii sporozoite cDNA library (generously provided by Dr. M. W. White, Montana State University) by the use of the primers TgHAD-2SCP-2N and TgHAD-2SCP-2C (see Supplemental Table S1 for all the sequences of primers used in this study). Amplified fragments (
1.9 kb) were subcloned into pCR2.1 by using the TOPO-TA cloning protocol (Invitrogen, Carlsbad, CA), and the insertion was confirmed by enzymatic digestion with EcoRI and sequencing. The cDNA sequence of TgHAD-2SCP-2 has been deposited in GenBank under the accession number EU348731.
Recombinant Peptide Expression in Escherichia coli and Affinity Purification
Two plasmids have been engineered to produce recombinant peptides. One corresponds to the second SCP-2 domain or SCP-2b (TgHAD-2SCP-2513-629) used for functional studies, and the other one encompasses the C terminus of the D-3-hydroxyacyl-CoA dehydrogenase domain (HAD) domain and the two SCP-2 domains (TgHAD-2SCP-2296-629; see Supplemental Figure S3) and was used to generate antibodies. The coding sequence corresponding to SCP-2b was PCR-amplified using the primers SCP-2-N1 and SCP-2-C1 (Supplemental Table SI) and directly cloned into the BamHI and HindIII sites of the pQE-30 vector (QIAGEN, Hilden, Germany) to generate N-terminal 6-His tagged fusion protein. The coding sequence corresponding to TgHAD-2SCP-2296-629 was polymerase chain reaction (PCR)-amplified using the primers SCP-2-N2 and SCP-2-C1 (Supplemental Table SI) and cloned into the SacI and HindIII sites of the above-mentioned vector to produce an N-terminal 6-His–tagged fusion protein. The recombinant peptides expressed in E. coli M15 strain were purified under denatured condition on Ni2+-nitrilotriacetic acid resin according to the QIAGEN protocol. After purification, the peptides were refolded by diluting the sample 10 times in the refolding buffer (50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 M L-arginine, 1 mM reduced form of glutathione, and 0.8 mM oxidized form of glutathione) at 4°C overnight. The samples were then concentrated and dialyzed against phosphate-buffered saline (PBS).
Plasmid Construction for Expression in Toxoplasma
Several plasmids were engineered for functional and localization studies of TgHAD-2SCP-2. To generate T. gondii stably expressing exogenous copies of TgHAD-2SCP-2, two different plasmids were constructed based on two T. gondii expression vectors: sagCATsag_Tub2358YFP and pTub-GFP obtained from the Roos laboratory (University of Pennsylvania). Both vectors facilitate the expression of recombinant proteins in T. gondii driven by the tubulin promoter, either with a C-terminal yellow fluorescent protein (YFP) fusion or with an N-terminal green fluorescent protein (GFP) fusion. The plasmid p1HA-TgHAD-2SCP-2 was based on psagCATsag_Tub2358YFP. To construct p1HA-TgHAD-2SCP-2, the TgHAD-2SCP-2 sequence was modified by PCR using primers HA-HAD-2SCP-2-N1 and HA-HAD-2SCP-2-C1 resulting in a fusion protein with the HA tag at the N-terminus. In this construct, a stop codon in the reverse primer was introduced before the YFP coding sequence. The sequence was ligated through BglII and AvrII in the expression vector. The plasmid psagCATsag_Tub2358YFP was also used for the construction of pTgHAD-2SCP-2-YFP to express the chimeric protein TgHAD-2SCP-2-YFP. The primers used for the PCR modification were HAD-2SCP-2-YFP-N and HAD-2SCP-2-YFP-C, which allows the ligation of the sequence between BglII and AvrII. To obtain the chimeric protein GFP-TgHAD-2SCP-2, the plasmid pGFP-TgHAD-2SCP-2 was produced using the expression plasmid pTub-GFP. For that construct, the 5' and 3' ends of TgHAD-2SCP-2 sequence was PCR-modified using the primers HAD-2SCP-2-YFP-N and GFP-HAD-2SCP-2-C and directly ligated to the BglII and AflII sites of pTub-GFP.
Plasmids pHA-SCP-2a, pHA-SCP-2b, and pHA-SCP-2b
SRL that correspond to N-terminal HA-tagged SCP-2a, SCP-2b, and SCP-2b in which the –SRL motif has been deleted (SRL), were also expressed in T. gondii. These plasmids were constructed using the expression vector sagCATsag_Tub2358YFP. PCR were run using the full-length of TgHAD-2SCP-2 as a template and the following primers: HA-SCP-2a-N and HA-SCP-2a-C for pHA-SCP-2a; HA-SCP-2b-N and HA-HAD-2SCP-2-C1 for pHA-SCP-2b; HA-SCP-2b-N and HA-SCP-2bSRL-C for pHA-SCP-2bSRL. A stop codon was introduced before the YFP coding sequence in the reverse primers. The three PCR products were then digested with BglII and AvrII and ligated to the corresponding sites in sagCATsag_Tub2358YFP. Using the same approach, six plasmids with single amino acid mutations derived from pHA-SCP-2a (pHA-SCP-2aM345K, pHA-SCP-2aI433K, and pHA-SCP-2aK434A) or pHA-SCP-2b (HA-SCP-2bM519K, HA-SCP-2bL608K, and HA-SCP-2bK609A) were engineered using the following primers: HA-SCP-2aM345K-N and HA-SCP-2a-C for pHA-SCP-2aM345K, HA-SCP-2a-N and HA-SCP-2aI433K-C for pHA-SCP-2aI433K, HA-SCP-2a-N and HA-SCP-2aK434A-C for pHA-SCP-2aK434A, HA-SCP-2bM519k and HA-HAD-2SCP-2-C1 for HA-SCP-2bM519K, HA-SCP-2b-N and HA-SCP-2bL608K-C for pHA-SCP-2bL608k, and HA-SCP-2b-N and HA-SCP-2bK609A-C for pHA-SCP-2bK609A.
Expression Analysis in T. gondii and Selection of Parasite Stable Lines
Expression plasmids containing the parasite sequences were grown in E. coli DH-5 and isolated using QIAGEN Plasmid Purification kits. Parasites were transfected by electroporation according to a published protocol (Roos et al., 1994). For generation of parasites stably expressing tagged versions of TgHAD-2SCP-2 or SCP-2 domains, parasites were transfected, passaged twice in HFF cultures under chloramphenicol selection, and cloned by limiting dilution in 96-well plates.
Plasmid Construction for Expression in Mammalian Cells
Six plasmids were engineered for functional and localization studies of TgHAD-2SCP-2. The pcDNA3.1 vector, which allows the expression of proteins with a myc-tag at its C terminus driven by a cytomegalovirus promoter, was used. For the construction of the plasmid pmyc-TgHAD-2SCP-2, the 5' and 3' ends of TgHAD-2SCP-2 were PCR modified using primers myc-HAD-2SCP-2-N and SCP-2-C1. The forward primer contains the sequence of myc-tag permitting the introduction of the tag at the N terminus of the resulting protein, and the reverse primer contains a stop codon to block the expression of C-terminal myc-tag. For pTgHAD-2SCP-2-myc engineering, the primers HAD-2SCP-2-myc-N and HAD-2SCP-2-myc-C were used for PCR modification to generate TgHAD-2SCP-2-myc. To construct pmyc-SCP-2b, which harbors the sequence of SCP-2b with an N-terminal myc-tag fusion, primers myc-SCP-2-N and SCP-2-C1 were used for the PCR amplification. All three modified PCR fragments were cloned into pcDNA3.1 vector through the EcoRI and HindIII sites.
Three other plasmids, pHA-SCP-2a, pHA-SCP-2b, and pTgHA-SCP-2bSRL were engineered similarly to the construction of pmyc-SCP-2b. Using TgHAD-SCP-2 as the template, SCP-2a or SCP-2b was PCR modified, and the resulting product was directly ligated into EcoRI and HindIII sites of pcDNA3.1. The primers used were SCP-2a-N and SCP-2a-C for pTgHA-SCP-2a, SCP-2b-N and SCP-2-C1 for pTgHA-SCP-2b, and SCP-2b-N and SCP-2bSRL-C for pTgHA-SCP-2bSRL. The forward primers contain an HA tag coding sequence to result in N-terminal HA-tagged peptides, and the reverse primers contain a stop codon before the restriction site HindIII to block the translation of downstream myc-tag sequence.
Expression Analysis in Mammalian Cells and Selection of Stable Cell Lines
Transfection of NIH3T3 cells and COS cells with pmyc-TgHAD-2SCP-2, pTgHAD-2SCP-2-myc, pHA-SCP-2a, pHA-SCP-2b, or pTgHA-SCP-2bSRL was completed using lipofectamine method according to the protocol (Invitrogen). For transfection of ZF with pmyc-SCP-2, both lipofectamine method and human dermal fibroblast nucleofactor kit (Amaxa Biosystems, Gaithersburg, MD) were used, and stable cell line was established by selecting on geneticin (Invitrogen).
Generation of Antibodies against TgHAD-2SCP-2296-629
To monitor TgHAD-2SCP-2 expression, rabbit polyclonal antisera were generated using the His-tagged recombinant TgHAD-2SCP-2296-629 (Covance, Berkeley, CA). Before use, the sera containing antibodies against TgHAD-2SCP-2296-629 (referred as anti-TgHAD-2SCP2 antibodies) were affinity-purified against the recombinant SCP-2b according to the protocol by AminoLink kit (Pierce Chemical).
Immunoblot Analysis of Wild-Type Parasites and Transfectants
For immunodetection, wild-type and transgenic parasites were lysed by suspension in SDS gel-loading buffer (50 mM Tris-HCl, pH 6.8, 50 mM 2-mercaptoethanol, 2% SDS, 0.1% bromphenol blue, and 10% glycerol) followed by boiling in a water bath. The samples were subjected to SDS-polyacrylamide gel electrophoresis (PAGE), and the proteins were then electrophoretically transferred to a membrane (Immobilon transfer membranes; Millipore, Billerica, MA). The membrane was immersed in blocking buffer (phosphate-buffered saline [PBS] containing 3% skim milk) for 60 min, and then incubated with anti-TgHAD-2SCP-2(1:1000), anti-HA antibody (1:5000) or anti-GFP antibodies (1:1000) in the blocking buffer for 60 min. Unbound antibody was removed by washing the membrane six times with blocking buffer. Next, the membrane was incubated with horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G (IgG) antibody (1:10,000; GE Healthcare) in blocking buffer for an additional hour, before detection by chemiluminescence using ECL-Plus (GE Healthcare).
Preparation and Treatment of Crude Vesicle Preparations Containing TgHAD-2SCP-2
T. gondii expressing HA-TgHAD-2SCP-2 (freshly lysed out of host cells) were filtered through 3-µm filter and collected by centrifugation at 1300 x g for 10 min at 4°C. After washing in PBS, transfectants (109 parasites) were then homogenized before low-speed centrifugation to eliminate large debris as described previously (Bradley et al., 2005). The supernatant was centrifuged at 50,000 x g for 90 min to obtain a high-speed organellar pellet. After extensive washing of the pellet, a fraction was mixed with protease inhibitors (1 mM EDTA; Complete protease inhibitor mixture), whereas another fraction was first treated with proteinase K (final concentration, 300 µg/ml) for 30 min at 4°C and then with phenylmethanesulfonyl fluoride (final concentration, 500 µg/ml). After these treatments, proteins from these fractions were precipitated with trichloroacetic acid and subjected to Western blotting analysis using anti-TgHAD-2SCP-2 and anti-HA antibodies.
NBD-labeled Lipid Binding to SCP-2
NBD-labeled cholesterol or NBD-labeled PC were selected to determine the interaction of those lipids with recombinant SCP-2b as described previously (Avdulov et al., 1999). Briefly, 0.2 µl of NBD-labeled lipids (1 x 10–3 M cholesterol or 1 x 10–4 M PC dissolved in dimethylformamide) was repeatedly added to 1 ml of sample buffer (PBS, in the presence or the absence of 1 µl of 6.7 x 10–7 M of SCP-2b) and stirred for 3 min before excitation at 460 nm and measurement of fluorescence intensity emitted at 550 nm by using a PerkinElmer fluorescence instrument (PerkinElmer Life and Analytical Sciences, Boston, MA). Scatchard plot was used to determine the Kd and Bmax values of these lipids to SCP-2b.
Spectrofluoremetric Assay to Monitor SCP-2b-mediated PC Transfer Activity
A fluorescence-based direct binding assay was used for measuring the transfer of PC between two bilayer vesicle populations in the presence of SCP-2b. Practically, small unilamellar bovine brain sphingomyelin/cholesterol mixed (6:1) acceptor vesicles or donor vesicles containing BODIPY-PC were prepared by probe sonication as described previously (Mattjus et al., 1999; Edqvist et al., 2004). Equal volume of donor vesicles and acceptor vesicles were vortexed, resulting in final phospholipid concentrations of 0.025 and 0.25 mM for the donor and acceptor, respectively.
To identify potential substrates for SCP-2b, competition assays were performed using unlabeled lipids and BODIPY-PC incorporated into donor vesicles. The efficiency of competition was determined by measuring the decrease in BODIPY fluorescence emission. These fluorescence dequenching assays started by addition of 1 µg of SCP-2b (0.06 µM) to BODIPY-PC incorporated into liposomes as described above, and after a steady transfer rate was reached, 2 µg of competing unlabeled lipids was added as liposomes to the reaction mixture as described previously (Edqvist et al., 2004). After correction for direct excitation of BODIPY in the absence of protein, the decrease in fluorescence emission was normalized relative to the decrease observed with liposomes without competitor. The displacement of BODIPY from SCP-2 by competing lipid substrates was analyzed by fitting the normalized fluorescence decrease to a hyperbolic function.
Cell Surface Transport Assay of Newly Synthesized Cholesterol
Confluent transfected ZFs and COS cells were incubated in MEM containing 10% lipoprotein-deficient serum (LPDS; prepared as described in Coppens et al., 2000) for 48 and 24h, respectively. After 24 h, COS cells were transiently transfected with myc-TgHAD-2SCP-2, HA-TgSCP-2a, HA-TgSCP-2b, or HA-TgSCP-2bSRL and maintained for one additional day in MEM plus 10% LPDS. On day 3, cells were pulsed with 20 µCi of [14C]acetate in ethanol (<1% final concentration) for 7 min at 37°C. The medium was removed and the label was chased by the addition of MEM containing 10 mM sodium acetate for the indicated chase times. Cells were then washed twice in the assay buffer (310 mM sucrose, 1 mM MgSO4, and 0.5 mM sodium phosphate, pH 7.4) at 25°C. Cholesterol oxidase (0.5 IU/ml) was added in the assay buffer, and the cells were incubated for 3 min at 25°C in conditions described previously (Brasaemle and Attie, 1990). The assay buffer was removed, and the cells were immediately extracted with chloroform:methanol (2:1). The chloroform phase was dried under nitrogen, resuspended with chloroform:methanol (1:1), and applied together with standards to a TLC plate. Plates were developed in hexane:ethyl ether:acetic acid (87:20:1) and visualized with iodine vapor. Spots were scraped and counted in a liquid scintillation counter. In a separate set of experiments, NHFs, transfected ZFs, and transfected COS cells were exposed 30 µCi of [14C]acetate for 7 min at 37°C to monitor cholesterol synthesis compared with mock-transfected ZF and mock-transfected COS cells. After the pulse, cells were incubated for 10, 20, 30, 40, and 60-min in the chase medium before washing. Lipids were extracted for total radioactive cholesterol recovery by TLC by using the solvent described above.
Lipid Uptake and Incorporation Assays in Mammalian Cells
For lipid uptake assays, confluent control ZF, SCP-2b–expressing ZFs, control COS cells, and COS cells expressing TgHAD-2SCP-2 or TgSCP-2bSRL were incubated in MEM with 10% FBS containing either 5 µCi of [14C]oleate conjugated to bovine serum albumin (BSA) or 30 µCi [3H]cholesterol incorporated into LDLs (prepared as described in Coppens et al., 1995) for 3 h at 37°C. Cells were then washed at 4°C, twice with PBS-Ca2+ (137 mM NaCl, 5.4 mM KCl, 0.34 mM Na2HPO4, 0.44 mM KH2PO4, 3.6 mM CaCl2, and 0.8 mM MgSO4, at pH 7.4) containing 1% (wt/vol) BSA and then twice with PBS-Ca2+ alone. Washed cells were lysed in 1 ml of 1% (wt/vol) sodium deoxycholate, pH 11.3, for protein content and radioactivity determination. For assays of oleate metabolism, cells were incubated in MEM with 10% FBS containing 25 µCi of [14C]oleate-BSA for 20-min at 37°C, then washed as described above. After lipid extraction in chloroform:methanol (2:1), the chloroform layer was separated from the aqueous layer by centrifugation, evaporated under nitrogen, and either resuspended in chloroform:methanol (2:1) for phospholipid recovery (PC and phosphatidylethanolamine) followed by TLC chromatography using chloroform:methanol:water (100:42:6), or resuspended in chloroform for triacylglycerol (TAG) and cholesteryl ester separation by TLC chromatography using petroleum ether:diethyl ether:acetic acid (80:20:1) as solvent. Bands were cut, and their radioactivity was measured by liquid scintillation counting.
Lipid Uptake and Incorporation Assays in T. gondii
For lipid uptake assays, HFFs were infected with control parasites or T. gondii expressing HA-TgSCP-2a, HA-TgSCP2-b, HA-TgSCP-2bSRL, HA-TgSCP-2aM345K, HA-TgSCP-2bM5195K, HA-TgSCP-2aI433K, HA-TgSCP-2bL608K, HA-TgSCP-2aK434A,or HA-TgSCP-2bK609A for 48 h before incubation in MEM with 10% FBS containing 15 µCi of [14C]oleate-BSA (C18:1), 15 µCi of [14C]palmitate-BSA (C16:0), or 30 µCi of [3H]cholesterol-LDL for 6 h at 37°C. After washing, intracellular parasites were purified by density gradient using Nycodenz and isopycnic centrifugation as detailed previously (Coppens et al., 2000). Amounts of cell-associated lipids were determined by radioactivity and normalized by parasite protein content. For fatty acid incorporation assays, infected HFF were incubated in MEM with 10% FBS containing 35 µCi of [14C]oleate-BSA or of [14C]palmitate-BSA for 60 min. After washing and parasite isolation, protein concentration was determined on an aliquot, before lipid extraction and separation by TLC as described above.
Light and Electron Microscopy Studies
Light and epifluorescence microscopy were performed on infected cells seeded on sterile coverslips in 24-well culture dishes. Immunofluorescence assay (IFA) on parasites or mammalian cells were performed as described previously (Coppens and Joiner, 2003) by using as primary antibodies affinity-purified anti-TgHAD-2SCP-2 (1:100), anti-myc (1:100), anti-HA (1:1000), or anti-GFP (1:200), and as secondary antibodies (Invitrogen) anti-mouse and anti-rabbit IgG conjugated to either Alexa 488 or Alexa 594 before dilution at 1:2000. For detection of cholesterol or lipid bodies by fluorescence microscopy, intravacuolar parasites were fixed in paraformaldehyde, and treated as described previously (Coppens and Joiner, 2003; Quittnat et al., 2004). Slides were observed using a Nikon Eclipse E800 microscope equipped with a Spot RT charge-coupled device camera and processed using Image-ProPlus software (Media Cybernetics, Silver Spring, MD) before assembly using Adobe Photoshop (Adobe Systems, Mountain View, CA). For immunoelectron microscopy, Toxoplasma-infected cells were fixed in 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) in 0.25 M HEPES, pH 7.4, for 1 h at room temperature, and then in 8% paraformaldehyde in the same buffer overnight at 4°C. They were infiltrated, frozen, and sectioned as described previously (Nishikawa et al., 2005). The sections were immunolabeled with anti-TgHAD-2SCP-2 antibodies (1:20 in PBS/1% fish skin gelatin) and then with mouse anti-rabbit IgG antibodies, followed directly by 10-nm protein A-gold particles (Department of Cell Biology, Medical School, Utrecht University, Utrecht, The Netherlands) before examination with a Philips CM120 electron microscope (Eindhoven, The Netherlands) under 80 kV.
Protein Determination
Protein content was determined using the bicinchoninic acid assay (Smith et al., 1985) with BSA as a standard.
Statistical Analysis
For comparison of means, p was determined using analysis of variance against control (ANOVA 2).
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
). We named this multidomain protein TgHAD-2SCP-2. In contrast to many organisms in which the SCP-2 domain is also expressed from a unique gene, no gene coding for SCP-2 alone was detected in T. gondii.
The ORF of TgHAD-2SCP-2 was amplified by PCR from a sporozoite cDNA library and also by RT-PCR from tachyzoite total RNA (Supplemental Figure S1). The ORF is 1887 nucleotides, consists of nine exons, and encodes a polypeptide of 629 amino acids, with a predicted mass of 67.9 kDa. Located at the N terminus, the HAD domain contains 321 amino acids (predicted size, 35 kDa) and shares 51% identity and 71% similarity with the sequence of the human HAD domain present in DBP (see HAD alignment in Supplemental Figure S2). The first SCP-2 domain (SCP-2a, extending from amino acid 322-448; predicted size of 13-kDa) is directly connected to HAD and is separated from the second SCP-2 domain (SCP-2b, extending from amino acid 513-629; predicted size of 13-kDa) by 61 amino acids. SCP-2a and SCP-2b are 36% identical and 58% similar to each other. Essential amino acids for the sterol transfer function are conserved in both SCP-2 domains (Figure 1A–B). Accordingly, tertiary structural analysis of the parasite SCP-2 domains by using Swiss-Prot software suggests that their core may also form a hydrophobic cavity through five-stranded β-sheets on one side covered by five -helices (Choinowski et al., 2000). The three C-terminal residues of SCP-2b, a tripeptide consisting of –SRL, suggest the presence of a putative PTS1 (Keller et al., 1991).
|
TgHAD-2SCP-2 Undergoes Multiple Processing Steps
In mammalian cells, fusion proteins carrying a SCP-2 domain are posttranslationally cleaved between the enzymatic portion and the SCP-2 domain (Gallegos et al., 2001). To determine whether TgHAD-2SCP-2 is cleaved to release SCP-2a and/or SCP-2b, lysates of wild-type parasites were analyzed by Western blotting using antibodies against the TgHAD-2SCP-2296-629 sequence (Figure 2). Data revealed three bands on immunoblots. The highest band, at 69 kDa (band A) and the lowest band at 13 kDa (band D), correspond to the predicted sizes of the full-length protein and separate SCP-2 domain, respectively. We hypothesize that the 36-kDa intermediate band (band B) represented either the HAD domain alone or SCP-2a still fused to SCP2b. To discriminate between these possibilities, we engineered a tagged version of TgHAD-2SCP-2. TgHAD-2SCP-2 was cloned from cDNA into a T. gondii expression vector and a HA tag was inserted at the N terminus (p1HA-TgHAD-2SCP-2). This construct was transfected into tachyzoites and stably integrated to generate the strain HA-TgHAD-2SCP-2 for Western blotting analysis. A major 70-kDa protein, corresponding to the predicted size of HA-tagged-TgHAD-2SCP-2 was recognized in this strain using either antibodies against TgHAD-2SCP-2296-629 or HA (Figure 2, b and c, band A). In addition, three minor bands at 37, 23, and 13 kDa could be generally detected using anti-TgHAD-2SCP-2 antibodies (Figure 2b, bands B–D), suggesting that the full-length 69-kDa protein is processed to generate three fragments. Using anti-HA antibodies against HA-TgHAD-2SCP-2 lysate (Figure 2c), we determined that the 37-kDa band corresponded to the HAD domain and that the 13-kDa band was likely SCP-2b. No 23-kDa band was identified using anti-HA antibodies, indicating that this band corresponds to SCP-2a fused to the linker region. Together, these observations suggest that TgHAD-2SCP-2 undergoes at least two processing steps that occur simultaneously. Indeed, no band corresponding to HAD connected to SCP-2a (expected size, 55-kDa) has been detected in our experiments. Further processing, e.g., trimming of the linker from SCP-2a, cannot be excluded. The absence of the 23-kDa band in wild-type parasites may be due to the rapid processing of SCP-2a after the removal of the linker, or alternatively overexpression of the protein may slow the posttranslational processing, allowing the visualization of intermediate cleavage products in HA-TgHAD-2SCP-2–expressing cells. When TgHAD-2SCP-2 was tagged with N-terminal GFP, only a single band at 100-kDa corresponding to uncleaved GFP-TgHAD-2SCP-2 was detected with anti-GFP antibodies (data not shown). This observation indicates that the N-terminal GFP tag likely interferes with posttranslational folding and processing of TgHAD-2SCP-2.
|
; Ding et al., 2000). The peroxisome targeting potential of the C-terminal –SRL motif of TgHAD-2SCP-2 was probed by expressing TgHAD-2SCP-2 with a N-terminal myc tag in fibroblasts expressing the peroxisomal protein catalase fused to GFP (Figure 3A, a–c). These experiments revealed a superimposable punctate pattern of TgHAD-2SCP-2 and catalase within the same cell, implying that the parasite protein localizes to mammalian peroxisomes. Control experiments were performed using a plasmid in which PTS1 was masked by the addition of a C-terminal myc tag (pTgHAD-2SCP-2-myc). In this case, the parasite protein yielded a staining spread through the cell (Figure 3Ad), which is consistent with a predicted endoplasmic reticulum (ER) and cytosolic localization (Edqvist et al., 2004).
|
). By comparison, no significant labeling of TgHAD-2SCP-2 could be detected above background in any other known compartment of Toxoplasma. Our data above indicate that TgHAD-2SCP-2 is cleaved into three products corresponding to the HAD, SCP-2a, and SCP-2b domains. To define the localization of specific domains, we transfected parasites with various constructs of TgHAD-2SCP-2 in fusion to an epitope tag at either the N terminus or the C terminus. Stable recombinant parasites expressing HA-TgHAD-2SCP-2 were labeled with anti-HA or anti-TgHAD-2SCP-2 antibodies (Figure 4A, a–c). Data illustrated a vesicular and cytosolic pattern, similar to that of wild-type parasites.
|
Next, we wanted to determine whether the C-terminal –SRL motif of SCP-2b functions as a targeting signal for vesicular localization of the protein within the parasite. Parasites stably expressing HA-TgSCP-2a, HA-TgSCP-2b, and HA-TgSCP-2b in which the –SRL motif has been deleted (HA-TgSCP-2bSRL) were constructed and stained with anti-HA antibodies for IFA (Figure 4C, a–e, and Supplemental Table S2). When parasites were transfected with HA-TgSCP-2a, the protein was exclusively cytosolic. By comparison, in HA-TgSCP-2b–expressing parasites, immunoreactivity to this domain increased within vesicles over the cytoplasm. This vesicular association was likely due to the –SRL motif because its ablation from TgSCP-2b resulted in cytosol distribution of the truncated domain. Parasites stably expressing TgHAD-2SCP-2 in fusion with YFP at the C terminus (TgHAD-2SCP-2-YFP strain) to abrogate PTS1 function were also tested. Expectedly, the chimeric protein was observed in the cytoplasm (Figure 4Cf). This suggests that, as described for the canonical PTS1 motif on peroxisomal proteins, the position of the –SRL motif at the C terminus of TgHAD-2SCP-2 seems critical to the proper subcellular localization of TgHAD-2SCP-2.
Toxoplasma SCP-2 Binds to Fluorescent Phosphatidylcholine and Cholesterol
Amino acids required for the lipid binding activity of SCP-2 (Stolowich et al., 2002) are conserved in both parasite SCP-2 domains (Figure 1A). A fluorescence based direct binding assay was performed to determine the capability of parasite SCP-2 to interact with cholesterol or PC. For this assay, we used an N-terminal His-tagged recombinant peptide corresponding to SCP-2b. Figure 5, A and B, shows titration-binding isotherms for the binding of NDB-cholesterol or NBD-PC to recombinant SCP-2b. Binding curves were saturable in the concentration range analyzed for both lipids. Scatchard plot analyses revealed a fit to a single class of sites (Figure 5, insets), with a Kd value of 1.01 ± 0.12 µM and a Bmax value of 1.01 ± 0.04 mol/mol for cholesterol and a Kd value of 0.11 ± 0.39 µM and a Bmax value of 2.45 ± 0.11 mol/mol for PC. Thus, SCP-2b shows lipid binding properties that are typical for this protein and displays the highest affinity for PC.
|
|
Cholesterol Delivery from the ER to the Plasma Membrane Is Accelerated in Zellweger Syndrome Fibroblasts Expressing Parasite SCP-2
A set of experiments was undertaken to investigate the physiological role of TgHAD-2SCP-2 in lipid circulation within cells. A role in cholesterol movement from the ER to the plasma membrane has been ascribed for SCP-2 (Puglielli et al., 1995). In ZFs, a cell line deficient in the import of PTS proteins and lacking SCP-2, the transfer of newly synthesized cholesterol to the surface is indeed slower compared with normal cells. We therefore probed the potentiality of parasite TgSCP-2b to accelerate the delivery of endogenous cholesterol to the surface of ZF in comparison with SCP-2 from NHF. Because ZF do not express DBP, we engineered a stable ZF cell line expressing TgSCP-2b (and not TgHAD-2SCP-2), based on the assumption that the machinery for processing the full-length protein may be impaired in ZF. We probed the localization of TgSCP-2b in ZF. ZF have remnant peroxisomes present as membrane ghosts and contain peroxisomal proteins that are mislocalized to the cytosol. Expectedly, IFA revealed that TgSCP-2b was localized to the cytoplasm of transfected ZFs (Figure 7A). We used pulse-chase experiments with radioactive acetate to study the rate at which newly synthesized cholesterol occurred at the cell surface. TgSCP-2b–expressing ZFs, untransfected ZF and NHF showed no difference in the amounts and rate of [14C]acetate incorporation into cholesterol, indicative of a comparable rate of cholesterol synthesis (Supplemental Figure S4). The half-times for the appearance of radiolabeled cholesterol at the plasma membrane were 5 and 7 min after the beginning of the pulse in NHF and SCP-2b–expressing ZF, respectively, whereas a value of 35 min was observed for untransfected ZFs under the same conditions.
|
SRL showed cytosolic distribution in COS cells, whereas TgSCP-2b localized both to peroxisome-like structures and cytosol. Comparison between transfected COS cells expressing parasite SCP-2 domains and untransfected control cells showed a moderate but significant increase in the kinetics of cholesterol delivery from the ER to the plasma membrane in the cells transfected with TgSCP-2a and TgSCP-2bSRL, whereas no difference in cholesterol synthesis was observed between transfected and untransfected COS cells (Supplemental Figure S4). These experiments favor a role for the cytosolic forms of the TgSCP-2 domains in facilitating the movement of cholesterol from the interior of the cell to the surface.
Parasite SCP-2 Enhances Lipid Uptake and Synthesis in Mammalian Cells
In mammalian cells, SCP-2 has multiple roles in intracellular lipid diffusion and metabolism (Gallegos et al., 2001; Murphy, 2002). To specify the properties of the parasite SCP-2 in modulating cellular lipid levels, transfected ZF expressing SCP-2b and transfected COS cells expressing TgHAD-2SCP-2 or TgSCP-2bSRL were incubated in the presence of radiolabeled oleate and cholesterol to monitor the uptake of these lipids (Figure 8A). After 3-h incubation with the radiolabeled compounds, the expression of the parasite SCP-2 in mammalian cells resulted in an increase in [14C]oleate uptake by 40% in ZF and by 45–50% in COS cells compared with their mock transfected controls. The uptake of [3H]cholesterol was comparable in transfected ZF expressing SCP-2b and controls. By contrast, COS cells expressing TgHAD-2SCP-2 or TgSCP-2bSRL incorporated 2 to 2.5 times more cholesterol compared with control cells.
|
SRL were incubated with radioactive oleate. Separation of phospholipids and esterified neutral lipids from these cells by TLC revealed that oleate was further incorporated into various lipids (Figure 8B). TgHAD-2SCP-2 expression increased the formation of total phospholipids by 2.1-fold, triglycerides by 1.9-fold and cholesteryl oleate by 2.4-fold. Tg2SCP-2bSRL expression also resulted in increase in lipid synthesis with values of 2.3-fold for phospholipids, 2.8-fold for triglycerides, and 3.1-fold for cholesteryl oleate.
Exogenous Expression of TgHAD-2SCP-2 in Toxoplasma Results in Increased Uptake and Metabolism of SCP-2 Lipid Substrates
Prompted by the observed effects of parasite SCP-2 in mammalian cells, the last series of experiments was focused on the potential of TgHAD-2SCP-2 in regulating lipid transport, synthesis and storage in T. gondii. Experiments were performed on parasites expressing HA-TgHAD-2SCP-2 and compared with mock transfected wild-type parasites in a gain-of-function phenotype-driven approach. Parasites were labeled with the fluorescent dye filipin, used for detection of membrane sterols, and HA-TgHAD-2SCP-2 expressors showed a brighter overall fluorescence than wild type (Figure 9A). These parasites were labeled in parallel with Nile red, a fluorescent lipid body dye (Figure 9B). Compared with control parasites that displayed lipid bodies throughout the cytoplasm without any specific location (Quittnat et al., 2004), T. gondii expressing HA-TgHAD-2SCP-2 showed an accumulation of lipid bodies at the posterior end, and sometimes in the vacuolar space (Figure 9B, arrows). The concentration of lipid bodies at the basal pole of the parasites where SCP-2 is also accumulated (Figure 4) suggests that this protein plays a role in lipid circulation and association with lipid bodies.
|
), we monitored the replication rate of HA-TgHAD-2SCP-2 expressors compared with wild-type parasites. Results showed that additional copies of TgHAD-2SCP-2 conferred an advantage to parasite growth as measured by enumeration of parasites per PV in infected cells (Figure 9C). Indeed, at 24 h post infection (p.i.), 10% of the PV from transfectants contained 16 parasites versus <1% among wild-type parasites.
To validate our morphological studies, the uptake of exogenous lipids was then monitored in Toxoplasma-infected cells exposed to radiolabeled lipids, followed by parasite purification and radioactivity determination (Figure 10). Data showed that parasites stably expressing HA-TgHAD-2SCP-2 accumulated higher amounts of [14C]oleate and [3H]cholesterol (or derived products), compared with control parasites. No significant difference was observed with respect to [14C]palmitate internalization between the two parasite strains, which is in agreement with the lack of evidence for SCP-2b binding to palmitate (Figure 6). We next evaluated the contribution of each SCP-2 domain in the uptake of radioactive oleate or cholesterol, and in the synthesis of cholesteryl oleate and phospholipid from radioactive oleate (Table 1). For parasites expressing HA-TgSCP-2b or HA-TgSCP-2bSRL, we observed a significant increase in oleate uptake. However, HA-TgSCP-2b expressors also showed a higher incorporation of exogenous oleate in cholesteryl oleate and total phospholipids, compared with wild-type parasites. HA-TgSCP-2a expression did not result in increased lipid uptake although a significant stimulation in cholesteryl oleate synthesis was observed.
|
|
Jointly, these observations suggest to some extent, selective roles for TgSCP-2a and TgSCP-2b domains in mediating the uptake of cholesterol and oleate into the parasites and redistributing of these lipids to lipid synthesis and storage sites.
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
). Subsequent to diverting host lipid to the PV, Toxoplasma must be able to import these exogenous lipids from the plasma membrane and to distribute them to various compartments. In this study, we reveal the role of a SCP-2 protein homologue for intracellular transportation, metabolism, and storage of host lipids in the parasite.
Toxoplasma SCP-2a and SCP-2b are members of the SCP-2 protein family. In contrast to many organisms, an SCP-2 in this parasite is not coded by a separate gene but is instead expressed in fusion with the enzyme D-3-hydroxyacyl-CoA dehydrogenase and a second SCP-2. Phylogenetic analysis reported that the multidomain TgHAD-2SCP-2 protein represents an alternative version of the large protein DBP, in which two enzymatic domains, D-3-hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase are connected to a single SCP-2 domain (Edqvist and Blomqvist, 2006). In mammalian cells, the SCP-2 domain harbors a PTS1 and is responsible for the transport of DBP to peroxisomes (Gould et al., 1989). In peroxisomes, DBP undergoes proteolytic cleavage at a site between the two enzymatic domains. These domains take part in peroxisomal oxidation of fatty acids through D-3-hydroxyacyl-CoA intermediates. It is possible that SCP-2 facilitates these reaction cycles by providing lipid substrates to the enzymatic active sites.
The presence of HAD expressed in Toxoplasma is mystifying because integrated computational genomics ascertain the absence of functional pathways linked to fatty acid oxidation in this parasite. We showed that TgHAD-2SCP-2 is cleaved between the HAD domain and SCP-2a, and in the region between the two SCP-2 domains. After the TgHAD-2SCP-2 processing, the SCP-2 domains can potentially exert versatile cellular activities unrelated to fatty acid catabolism in Toxoplasma. From an evolutionary point of view, we speculate that if HAD is useless for the parasite, the presence of the TgHAD-2SCP-2 gene in the Toxoplasma genome is more likely to reflect a need to retain the SCP-2 domain. A recent systematic investigation on the evolution of SCP-2 domains in eukaryotic organisms reveals indeed that over the course of evolution, SCP-2 has been subjected to many genetic duplications, fissions, and fusions, from the point of its earliest appearance in the ancestral D-3-hydroxyacyl-CoA dehydrogenase/SCP-2 fusion (Edqvist and Blomqvist, 2006).
The majority of SCP-2 expressed in eukaryotic organisms harbor a PTS1 as found in peroxisomal matrix proteins. Likewise, the C-terminal –SRL of TgHAD-2SCP-2 matches the consensus of a PTS1, and we evidenced here that this motif represents a subcellular localization signal in the parasite. Shifting the PTS1 of TgHAD-2SCP-2 from the C terminus toward the center of TgHAD-2SCP-2 (in the Tg-HAD-2SCP-2-YFP construct) or deleting this motif from TgSCP-2b results in the cytosolic localization of the protein. This suggests that, like mammalian SCP-2, the C-terminal accessibility of TgHAD-2SCP-2 is critical for the interaction of –SRL with a receptor, and therefore the proper localization of the protein in the parasite.
In mammalian cells, the 58-kDa SCP-x protein is partially posttranslationally cleaved to a N-terminal 46-kDa protein (3-oxoacyl-CoA thiolase) and a C-terminal 13-kDa SCP-2 (Gallegos et al., 2001). So far, no information exists about the mechanism of cleavage—by autocatalysis or protease mediation—of mammalian SCP-2–containing proteins or about the cleavage site residues. The 58-kDa SCP-x is almost exclusively a peroxisomal protein and several observations support that posttranslational proteolysis of this protein occurs in peroxisomes either on the cytoplamic face of these organelles or inside their matrix. In view of that, Zellweger cells lacking peroxisomes express 58-kDa SCP-x but no 13-kDa SCP-2 can be detected. In most cells, 13-kDa SCP-2 has also a cytosolic localization, which implies that this domain cleaved from SCP-x must be leaked from the peroxosimes by an as yet unknown mechanism.
We have established that TgHAD-2SCP-2 undergoes at least two processing steps that occur simultaneously, which results in the release of an N-terminal 37-kDa HAD and two separate 13-kDa SCP-2 domains. Our data showed that TgHAD-2SCP-2 copurifies with parasite vesicles, indicating that after synthesis in the cytosol, the unprocessed protein is delivered to specific compartments, probably through the C-terminal –SRL motif. The lack of detection of any cleaved domains, HAD or SCP-2, on vesicles suggests either that these organelles, in contrast to mammalian peroxisomes, are maybe not the site of proteolytic cleavage of TgHAD-2SCP-2 or that partial cleavage of the protein may take place in vesicles but HAD and SCP-2 are rapidly transferred out of the vesicles to the cytosol. When parasites are transfected with a plasmid harboring the coding sequence of TgSCP-2b alone and examined by IFA, immunoreactivity to this domain increases within vesicles over the cytoplasm. This suggests that once in the cytoplasm, SCP-2b may redistribute to vesicles, although the possibility that different populations of SCP-2–containing vesicles exist cannot be discounted.
The import of TgHAD-2SCP-2 into mammalian peroxisomes involves that the PTS1 present in the parasite sequence can interact with a mammalian PTS1 receptor. In mammalian cells, recognition of PTS1 is facilitated by the protein receptor peroxin 5 (PEX5), which cycles between the cytosol and peroxisomes in mammalian cells (Dodt and Gould, 1996). However, searches in the T. gondii EST database for PEX5 homologue was fruitless although putative PEX11, PEX7, and PEX1 could be retrieved by sequence homologies [expectation values from e–23 to e–56]. Mammalian PEX7 is a cytosolic and peroxisomal receptor for peroxisomal proteins carrying a membrane PTS2 (mPTS2) at the N terminus, whereas PEX11 and PEX1 are required for peroxisome fusion/division (Titorenko and Rachubinski, 2001). Our data demonstrated that SCP-2 protein is membrane-bound in vesicles, suggesting that a PTS2 targeting pathway may be used by the protein though no conventional mPTS2 is detectable in the TgHAD-2SCP-2 sequence. In mammalian cells, SCP-2 has a primary localization to peroxisomes but can also be found on the cytosolic face of the ER or inside mitochondria (Gallegos et al., 2001), two organelles with lipid metabolic properties. The absence of SCP-2a or SCP-2b from parasite ER and mitochondria may reflect the limited capabilities of the parasite for lipid synthesis or processing.
Peroxisomes or microbody-like structures have never been unambiguously identified in Toxoplasma (Kaasch and Joiner, 2000; Ding et al., 2000). Given the detection in T. gondii of enzymes involved in the glyoxylate cycle, the presence of glyoxysome-like organelles, which house fatty acid conversion to succinate and ultimately to glucose, is plausible. Common enzymes for peroxisomes include catalase and peroxidase that are involved in the decomposition of hydrogen peroxide. Only catalase is present in the parasite. Toxoplasma catalase contains an atypical PTS1 but localizes to mammalian peroxisomes. One study illustrates that catalase is present primarily in punctate compartments anterior to the nucleus in T. gondii, which may correspond to peroxisomal structures (Kaasch and Joiner, 2000). Conversely, two other studies showed a cytosolic localization of GFP fused with the C-terminal 12 amino acids containing the putative PTS1 from T. gondii catalase or full-length catalase (Ding et al., 2000, 2004). A possible explanation for the results obtained by Ding and colleagues is that upstream sequence elements of catalase (beyond the C-terminal 12 amino acids) may modulate the targeting efficiency of catalase to parasite organelles. Indeed, PTS1 upstream sequences in many peroxisomal proteins contribute to the protein stability, carboxy-terminal accessibility or translocation into peroxisomes (Neuberger et al., 2004). It is known that Toxoplasma proteins contain evolutionarily conserved and unconventional targeting signals that direct proteins to specific organelles. Therefore, if Toxoplasma catalase is not associated with peroxisomal compartments despite the presence of a PTS1, the protein sequence may contain competing targeting signals that prevent the translocation of catalase into a compartment. An alternative hypothesis is that PTS1 motifs may have occurred as a result of neutral mutation during evolution. Indeed, organisms lacking peroxisomes such as bacteria express proteins that harbor a PTS1-like carboxy-terminal signal.
Peroxisomes are heterogeneous and dynamic organelles that differ in size (ranging in diameter from 0.1 to 1 µm), number and protein composition, depending on the organism, cell type, and environmental condition (Titorenko and Rachubinski, 2001). The characteristics of the parasite compartment containing TgHAD-2SCP-2 and cleaved products are compatible with the size of large spherical peroxisomes. Colocalization studies with peroxisomal markers would provide a definitive answer about the existence of a peroxisomal endomembrane system and functional PTS-like targeting pathways in T. gondii.
Of interest, parasites expressing exogenous copies of SCP-2 accumulate lipid bodies at the basal end. Compared with the apical end of the parasite, which contains specialized organelles with clearly defined localization, much less is known about the architecture, organization, and organelle composition of the basal end. Parasite division by endodyogeny, an internal budding process that creates two daughter cells inside the mother cell, seems to be coordinated at the basal end (Gubbels et al., 2006; Hu, 2008). Undeniably, this pole contains structural elements for daughter cell formation but how new membranous systems and organelles expand during progeny formation still remains elusive. In this context, the Toxoplasma SCP-2 domains may primarily play a role in parasite replication by providing the needed lipids for organellar membrane biosynthesis. Lipid bodies in Toxoplasma contain large amounts of neutral lipids such as cholesteryl esters and triacylglycerols (Quittnat et al., 2004; Nishikawa et al., 2005), which are synthesized by the parasite. The enhancement of cholesterol and oleate uptake and their incorporation into neutral lipids in SCP-2 expressors may be concurrent with the local concentration of neutral lipid stores at the posterior end. We can assume that cholesteryl esters and triacylgycerols stored at this area of T. gondii may constitute energy sources or a ready source of the lipids required for endodyogeny. Interestingly, a role for SCP-2 in stimulating cholesteryl ester formation and regulating fatty acid and cholesterol targeting to lipid bodies has been reported in fibroblasts transfected with SCP-2 (Atshaves et al., 2001). SCP-2 expression in fibroblasts dramatically influences the composition of the core and surface lipids of lipid bodies. No changes in lipid body size and no SCP-2 interaction with lipid bodies have ever been observed upon parasite SCP-2 overexpression in Toxoplasma or fibroblasts.
Cholesterol originating from the host cell must be translocated across the plasma membrane of T. gondii. In mammalian cells, SCP-2 can transfer sterols from the plasma membrane to the cell interior (e.g., to ER and lipid bodies; Moncecchi et al., 1996; Atshaves et al., 2001). SCP-2 colocalizes with caveolin-1 at the plasma membrane, and together these proteins enhance cholesterol transfer (Atshaves et al., 2003; Zhou et al., 2004). In yeast, nonvesicular sterol trafficking from the plasma membrane to the ER involves oxysterol-binding protein-related proteins (ORPs; Raychaudhuri et al., 2006). The genome of Toxoplasma does not encode any caveolin genes. Our unpublished data on the characterization of an ORP2 homologue in the parasite localized the protein to the PV (Zhang, Lige, and Coppens, unpublished). Our immunogold EM studies do not detect SCP-2a or SCP-2b on the parasite surface though weak, transient interaction between SCP-2 and the plasma membrane may occur.
The lack of fatty acid-binding proteins (FABPs) in Toxoplasma may confer for the two parasite SCP-2, a FABP-like function in facilitating uptake, trafficking, and targeting of fatty acids. Parasite SCP-2 expression in mammalian cells results in enhancement of cholesterol transfer from the ER to the plasma membrane. Whether this movement of cholesterol from the ER to the parasite surface is operational in T. gondii remains to be demonstrated because no sterols are synthesized by Toxoplasma on the ER. Parasite SCP-2 also acts as a substrate carrier for phospholipids, shows weak affinity for ergosterol, and cannot bind to ceramide and palmitate. Ergosterol has not been detected in Toxoplasma (Nishikawa et al., 2005), but palmitate is the most abundant fatty acid found in cholesteryl esters, n-acylglycerides, and glycosylphosphatidylinositol anchors in the parasite (Coppens, 2006). Thus, alternative transport pathways must exist to facilitate palmitate trafficking in the parasite.
Among the large phylum of Apicomplexa, only Eimeria tenella has a predicted gene encoding a separate SCP-2 protein carrying a PTS1 (–SKL; Edqvist and Blomqvist, 2006). No SCP-2, fused or separate, has been found in the genome of Plasmodium or Cryptosporidium sp. Toxoplasma constitutes a unique example of a protozoan pathogen expressing a multidomain protein carrying two SCP-2 domains. In this study, we provide the first experimental evidence that the Toxoplasma SCP-2 homologue plays multiple roles in cholesterol, fatty acid, and phospholipid metabolism, intracellular transportation, and deposition into specific lipid pools. Our data underline, on one hand, the evolutionarily conservation of the mechanism of nonvesicular lipid movement mediated by SCP-2, and on the other hand, the exploitation of this lipid carrier by an intracellular parasite to enhance host lipid uptake and use.
|
ACKNOWLEDGMENTS |
|---|
|
Footnotes |
|---|
Address correspondence to: Isabelle Coppens (icoppens{at}jhsph.edu).
Abbreviations used: DBP, D-bifunctional protein; HFF, human foreskin fibroblast; LDL, low-density lipoprotein; LPDS, lipoprotein-deficient serum; NHF, normal human fibroblast; PC, phosphatidylcholine; p.i., post-infection; PTS1, peroxisomal targeting signal 1; PV, parasitophorous vacuole; SCP-2, sterol carrier protein-2; TLC, thin layer chromatography; ZF, Zellweger syndrome fibroblast.
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Atshaves, B. P., Storey, S. M., McIntosh, A. L., Petrescu, A. D., Lyuksyutova, O. I., Greenberg, A. S., and Schroeder, F. (2001). Sterol carrier protein-2 expression modulates protein and lipid composition of lipid droplets. J. Biol. Chem 276, 25324–25335.
Atshaves, B. P., Gallegos, A. M., McIntosh, A. L., Kier, A. B., and Schroeder, F. (2003). Sterol carrier protein-2 selectively alters lipid composition and cholesterol dynamics of caveolae/lipid raft vs nonraft domains in L-cell fibroblast plasma membranes. Biochemistry 42, 14583–14598.[CrossRef][Medline]
Avdulov, N. A., Chochina, S. V., Igbavboa, U., Warden, C. S., Schroeder, F., and Wood, W. G. (1999). Lipid binding to sterol carrier protein-2 is inhibited by ethanol. Biochim. Biophys. Acta 1437, 37–45.[Medline]
Bradley, P. J. et al. (2005). Proteomic analysis of rhoptry organelles reveals many novel constituents for host-parasite interactions in Toxoplasma gondii. J. Biol. Chem 280, 34245–34258.
Brasaemle, D. L., and Attie, A. D. (1990). Rapid intracellular transport of LDL-derived cholesterol to the plasma membrane in cultured fibroblasts. J. Lipid Res 31, 103–112.[Abstract]
Choinowski, T., Hauser, H., and Piontek, K. (2000). Structure of sterol carrier protein 2 at 1.8 A resolution reveals a hydrophobic tunnel suitable for lipid binding. Biochemistry 39, 1897–1902.[CrossRef][Medline]
Coppens, I., Levade, T., and Courtoy, P. J. (1995). Host plasma low density lipoprotein particles as an essential source of lipids for the bloodstream forms of Trypanosoma brucei. J. Biol. Chem 270, 5736–5741.
Coppens, I., Sinai, A. P., and Joiner, K. A. (2000). Toxoplasma gondii exploits host low-density lipoprotein receptor-mediated endocytosis for cholesterol acquisition. J. Cell Biol 149, 167–180.
Coppens, I., and Joiner, K. A. (2003). Host but not parasite cholesterol controls Toxoplasma cell entry by modulating organelle discharge. Mol. Biol. Cell 14, 3804–3820.
Coppens, I. (2006). Contribution of host lipids to Toxoplasma pathogenesis. Cell. Microbiol 8, 1–9.[CrossRef][Medline]
Ding, M., Clayton, C., and Soldati, D. (2000). Toxoplasma gondii catalase: are there peroxisomes in Toxoplasma? J. Cell Sci 113, 2409–2419.[Abstract]
Ding, M., Kwok, L. Y., Schlüter, D., Clayton, C., and Soldati, D. (2004). The antioxidant systems in Toxoplasma gondii and the role of cytosolic catalase in defence against oxidative injury. Mol. Microbiol 51, 47–61.[CrossRef][Medline]
Dodt, G., and Gould, S. J. (1996). Multiple PEX genes are required for proper subcellular distribution and stability of Pex5p, the PTS1 receptor: evidence that PTS1 protein import is mediated by a cycling receptor. J. Cell Biol 135, 1763–1774.
Dyer, D. H., Lovell, S., Thoden, J. B., Holden, H. M., Rayment, I., and Lan, Q. (2003). The structural determination of an insect sterol carrier protein-2 with a ligand-bound C16 fatty acid at 1.35-A resolution. J. Biol. Chem 278, 39085–39091.
Edqvist, J., Rönnberg, E., Rosenquist, S., Blomqvist, K., Viitanen, L., Salminen, T. A., Nylund, M., Tuuf, J., and Mattjus, P. (2004). Plants express a lipid transfer protein with high similarity to mammalian sterol carrier protein-2. J. Biol. Chem 279, 53544–53553.
Edqvist, J., and Blomqvist, K. (2006). Fusion and fission, the evolution of sterol carrier protein-2. J. Mol. Evol 62, 292–306.[CrossRef][Medline]
Gallegos, A. M., Atshaves, B. P., Storey, S. M., Starodub, O., Petrescu, A. D., Huang, H., McIntosh, A. L., Martin, G. G., Chao, H. et al. (2001). Gene structure, intracellular localization, and functional roles of sterol carrier protein-2. Prog. Lipid Res 40, 498–563.[CrossRef][Medline]
Gould, S. J., Keller, G. A., Hosken, N., Wilkinson, J., and Subramani, S. (1989). A conserved tripeptide sorts proteins to peroxisomes. J. Cell Biol 108, 1657–1664.
Gubbles, M. J., Vaishnava, S., Boot, N., Dubremetz, J. F., and Striepen, B. (2006). A MORN-repeat protein is a dynamic component of the Toxoplasma gondii cell division apparatus. J. Cell Sci 119, 2236–2245.
Hu, K. (2008). Organizational changes of the daughter basal complex during the parasite replication of Toxoplasma gondii. PLoS Pathog 4, e10.[CrossRef][Medline]
Kaasch, A. J., and Joiner, K. A. (2000). Targeting and subcellular localization of Toxoplasma gondii catalase. Identification of peroxisomes in an apicomplexan parasite. J. Biol. Chem 275, 1112–1118.
Keller, G. A., Krisans, S., Gould, S. J., Sommer, J. M., Wang, C. C., Schliebs, W., Kunau, W., Brody, S., and Subramani, S. (1991). Evolutionary conservation of a microbody targeting signal that targets proteins to peroxisomes, glyoxysomes, and glycosomes. J. Cell Biol 114, 893–904.
Mattjus, P., Molotkovsky, J. G., Smaby, J. M., and Brown, R. E. (1999). A fluorescence resonance energy transfer approach for monitoring protein-mediated glycolipid transfer between vesicle membranes. Anal. Biochem 268, 297–304.[CrossRef][Medline]
Moncecchi, D., Murphy, E. J., Prows, D. R., and Schroeder, F. (1996). Sterol carrier protein-2 expression in mouse L-cell fibroblasts alters cholesterol uptake. Biochim. Biophys. Acta 1302, 110–116.[Medline]
Mukherji, M., Kershaw, N. J., Schofield, C. J., Wierzbicki, A. S., and Lloyd, M. D. (2002). Utilization of sterol carrier protein-2 by phytanoyl-CoA 2-hydroxylase in the peroxisomal oxidation of phytanic acid. Chem. Biol 9, 597–605.[CrossRef][Medline]
Murphy, E. J. (2002). Sterol carrier protein-2, not just for cholesterol any more. Mol. Cell. Biochem 239, 87–93.[CrossRef][Medline]
Neuberger, G., Kunze, M., Eisenhaber, F., Berger, J., Hartig, A., and Brocard, C. (2004). Hidden localization motifs: naturally occurring peroxisomal targeting signals in non-peroxisomal proteins. Genome Biol 5, R97.[CrossRef][Medline]
Nishikawa, Y., Quittnat, F., Stedman, T. T., Voelker, D. R., Choi, J. Y., Zahn, M., Yang, M., Pypaert, M., Joiner, K. A., and Coppens, I. (2005). Host cell lipids control cholesteryl ester synthesis and storage in intracellular Toxoplasma. Cell Microbiol 7, 849–867.[CrossRef][Medline]
Prinz, W. A. (2007). Non-vesicular sterol transport in cells. Prog. Lipid Res 46, 297–314.[CrossRef][Medline]
Puglielli, L., Rigotti, A., Greco, A. V., Santos, M. J., and Nervi, F. (1995). Sterol carrier protein-2 is involved in cholesterol transfer from the endoplasmic reticulum to the plasma membrane in human fibroblasts. J. Biol. Chem 270, 18723–18726.
Quittnat, F. et al. (2004). On the biogenesis of lipid bodies in ancient eukaryotes: synthesis of triacylglycerols by a Toxoplasma DGAT1-related enzyme. Mol. Biochem. Parasitol 138, 107–122.[CrossRef][Medline]
Raychaudhuri, S., Im, Y. J., Hurley, J. H., and Prinz, W. A. (2006). Nonvesicular sterol movement from plasma membrane to ER requires oxysterol-binding protein-related proteins and phosphoinositides. J. Cell Biol 173, 107–119.
Roos, D. S., Donald, R. G., Morrissette, N. S., and Moulton, A. L. (1994). Molecular tools for genetic dissection of the protozoan parasite Toxoplasma gondii. Methods Cell Biol 45, 27–63.[Medline]
Sehgal, A., Bettiol, S., Pypaert, M., Wenk, M. R., Kaasch, A., Blader, I. J., Joiner, K. A., and Coppens, I. (2005). Peculiarities of host cholesterol transport to the unique intracellular vacuole containing Toxoplasma. Traffic 6, 1125–1141.[CrossRef][Medline]
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985). Measurement of protein using bicinchoninic acid. Anal. Biochem 150, 76–85.[CrossRef][Medline]
Stolowich, N. J., Petrescu, A. D., Huang, H., Martin, G. G., Scott, A. I., and Schroeder, F. (2002). Sterol carrier protein-2, structure reveals function. Cell. Mol. Life Sci 59, 193–212.[CrossRef][Medline]
Titorenko, V. I., and Rachubinski, R. A. (2001). The life cycle of the peroxisome. Nat. Rev. Mol. Cell Biol 2, 357–368.[CrossRef][Medline]
Wenk, M. R. (2006). Lipidomics of host-pathogen interactions. FEBS Lett 580, 5541–5551.[CrossRef][Medline]
Zhou, M., Parr, R. D., Petrescu, A. D., Payne, H. R., Atshaves, B. P., Kier, A. B., Ball, J. M., and Schroeder, F. (2004). Sterol carrier protein-2 directly interacts with caveolin-1 in vitro and in vivo. Biochemistry 43, 7288–7306.[CrossRef][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
